Paeds Vivas · allergy-and-immunology
Anaphylaxis: recognition and emergency management — branching viva
Branching structured-oral viva on anaphylaxis: the mediator cascade and why adrenaline reverses it, the NIAID/FAAN criteria and the no-skin-signs pitfall, the weight/age IM adrenaline dose and site, the refractory escalation with an IV adrenaline infusion and glucagon, the tryptase timing and interpretation, and the biphasic observation and discharge package.
On this page
Study tools
Target exams
Opening question
Examiner: Take me through this adolescent. What is the diagnosis, and what is your frame for managing her? [1]
Candidate: This is anaphylaxis. She has acute respiratory compromise — wheeze and dizziness — and a distributive-shock picture — pallor and presyncope — after a likely food allergen in a known peanut-allergic child. That meets the NIAID/FAAN criteria for anaphylaxis even though she has no rash. My frame is simple: give intramuscular adrenaline now, without waiting for a rash or a test, then support the airway, breathing and circulation, escalate if she does not respond, and keep her for observation because a biphasic reaction can recur. [1]
Examiner: She has no skin signs at all. Does that worry you, or reassure you? [1]
Candidate: It worries me. Up to a fifth of anaphylactic reactions have no skin or mucosal signs, and this girl is exactly the high-risk profile — the asthmatic adolescent with food anaphylaxis. The absence of a rash is the pitfall that delays adrenaline in fatal cases, so it is the reason to act faster, not to pause. [1]
References6ShowHide
- [1]Sampson HA; Muñoz-Furlong A; Campbell RL; et al Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Ann Emerg Med, 2006.PMID 16546624
- [3]Simons FE; Ardusso LR; Bilò MB; et al World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J, 2011.PMID 23268454
- [4]Muraro A; Worm M; Alviani C; et al EAACI guidelines: Anaphylaxis (2021 update). Allergy, 2022.PMID 34343358
- [8]Sicherer SH; Simons FER; SECTION ON ALLERGY AND IMMUNOLOGY Epinephrine for First-aid Management of Anaphylaxis. Pediatrics, 2017.PMID 28193791
- [9]Lee S; Bellolio MF; Hess EP; et al Predictors of biphasic reactions in the emergency department for patients with anaphylaxis. J Allergy Clin Immunol Pract, 2014.PMID 24811018
- [10]Dribin TE; Sampson HA; Zhang Y; et al Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. Lancet Child Adolesc Health, 2025.PMID 40506197